Physiologically based pharmacokinetic models of small molecules and therapeutic antibodies: a mini‐review on fundamental concepts and applications
Authors:
- 30 March 2016
- journal article
- review article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 37 (2) , 75-92
Abstract
The mechanisms of absorption, distribution, metabolism and elimination of small and large molecule therapeutics differ significantly from one another and can be explored within the framework of a physiologically based pharmacokinetic (PBPK) model. This paper briefly reviews fundamental approaches to PBPK modeling, in which drug kinetics within tissues and organs are explicitly represented using physiologically meaningful parameters. The differences in PBPK models applied to small/large molecule drugs are highlighted, thus elucidating differences in absorption, distribution and elimination properties between these two classes of drugs in a systematic manner. The absorption of small and large molecules differs with respect to their common extravascular routes of delivery (oral versus subcutaneous). The role of the lymphatic system in drug distribution, and the involvement of tissues as sites of elimination (through catabolism and target mediated drug disposition) are unique features of antibody distribution and elimination that differ from small molecules, which are commonly distributed into the tissues but are eliminated primarily by liver metabolism. Fundamental differences exist in the ability to predict human pharmacokinetics based upon preclinical data due to differing mechanisms governing small and large molecule disposition. These differences have influence on the evolving utilization of PBPK modeling in the discovery and development of small and large molecule therapeutics. Copyright © 2015 John Wiley & Sons, Ltd.Keywords
This publication has 69 references indexed in Scilit:
- The Original Michaelis Constant: Translation of the 1913 Michaelis–Menten PaperBiochemistry, 2011
- Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic ModellingClinical Pharmacokinetics, 2011
- Physiologically based pharmacokinetic model for T84.66: A monoclonal anti-CEA antibodyJournal of Pharmaceutical Sciences, 2010
- Predicting Pharmacokinetics of Drugs Using Physiologically Based Modeling—Application to Food EffectsThe AAPS Journal, 2009
- A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragmentsMolecular Cancer Therapeutics, 2006
- A Predictive Model of Therapeutic Monoclonal Antibody Dynamics and Regulation by the Neonatal Fc Receptor (FcRn)Annals of Biomedical Engineering, 2005
- Prediction of Drug Distribution in Distribution Dialysis and In Vivo from Binding to Tissues and BloodJournal of Pharmaceutical Sciences, 1993
- In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic modelsJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital, and thiopental in the ratJournal of Pharmacokinetics and Biopharmaceutics, 1982
- Animal scale-upJournal of Pharmacokinetics and Biopharmaceutics, 1973